• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA approves Medtronic drug-eluting stents for treating bifurcation lesions

September 21, 2022 By Sean Whooley

Medtronic Resolute Onyx drug-eluting stent
The Resolute Onyx drug-eluting stent. [Image from Medtronic]
Medtronic (NYSE:MDT) announced today that the FDA approved its Onyx drug-eluting stents (DES) for treating certain lesions.

Approval covers the treatment of non-left main bifurcation lesions utilizing the provisional bifurcation stenting technique. The technique uses a single stent to treat the bifurcation in percutaneous coronary interventions (PCIs). It applies to the FDA-approved and CE-marked Onyx Frontier and Resolute Onyx drug-eluting stents.

Medtronic said in a news release that the indication allows for a robust portfolio of medical education and procedural training for PCIs.

Bifurcation lesions often present unique challenges for cardiologists, Medtronic said. Attributes found in the company’s stents “optimize the treatment” of such lesions. The drug-eluting stents feature a single-wire design to provide vessel conformability and side branch access. The design also offers the option to open the stent cell while maintaining consistent stent scaffolding.

Medtronic cited clinical evidence from the Resolute Onyx bifurcation study supporting the stents. Resolute Onyx demonstrated low event rates, the company said. It beat the performance goal for the primary endpoint of target vessel failure at one year. The study results support the safety and efficacy of both stents in non-left main bifurcation lesions using the provisional stenting technique.

“The bifurcation expanded indication is yet another exciting milestone for our Coronary business this year,” said Jason Weidman, SVP and president of Medtronic’s Coronary & Renal Denervation business. “As the first and only medical device company to offer this indication to U.S. interventional cardiologists, Medtronic remains committed to investing in DES technology, clinical evidence, and physician education.

“We are looking forward to helping even more physicians access the tools they need to give their patients best-in-class care.”

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Oncology, Regulatory/Compliance, Stents, Vascular Tagged With: FDA, Medtronic

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS